B2B ad examples

Zou het kunnen gaan om diepe-venetrombose (DVT)? Sommige risicofactoren liggen voor de hand. Andere vereisen een nadere blik. Verdiep u ter gelegenheid van Wereldtrombosedag in realistische patiëntscenario's, bedoeld om de discussie over DVT-risico's en patiëntenbescherming te stimuleren. #WorldThrombosisDay #DVT #VTEAwareness #CardinalHealth 🔗: https://lnkd.in/gmCUCPyr

Elke patiënt presenteert een ander klinisch beeld. Verken realistische patiëntscenario's en ontdek hoe kleine details van invloed kunnen zijn op gesprekken over het risico op DVT (diepe-veentrombose) en de bescherming van de patiënt. 🔗: https://lnkd.in/gmCUCPyr #WorldThrombosisDay #DVT #VTEAwareness #CardinalHealth

Your target class may already be curated: GOSTAR holds about 11 million compounds from patents and papers. Start from a ready cut, not a blank sheet.

A defensible landscape without pulling your team off their work. Excelra's PhD-led screening covers patents and papers, each finding traced to source.

Finally... a CRO experience sites actually want to repeat. 👀 Smoother workflows mean less back and forth, fewer operational headaches, and more time for the work that matters. Clincove helps CROs connect clinical trial workflows so teams and sites can work better together. Better workflows. Stronger site relationships. A more capable CRO. 🌍 Visit www.clincove.com 🗓️ Book a demo at https://lnkd.in/gEDTPDhw/?utm_campaign=BoostedVideos&utm_source=linkedin&utm_medium=paid&utm_id=1231102646&hsa_acc=519702221&hsa_cam=1231102646&hsa_grp=912261266&hsa_ad=1641180606&hsa_net=linkedin&hsa_ver=3 #ClinicalTrials #ClinicalResearch #ClinicalOperations #EDC #TrialManagement #LifeSciences #ResearchInnovation #CRO #DataIntegrity #ClinicalSoftware #ClinOps #ClinicalTrialOperations #ISF #TMF #SourceRecords

Interpreting complex 3D models requires confidence in what you’re measuring. Learn how confocal imaging supports cleaner Z-stacks, clearer multiplexed signals, and more accurate assessment of treatment effects in spheroids and immune co-cultures.

Fellowship-trained and board-certified, our founder Dr. Rahman specializes in complex scoliosis and spine care. Accepting referrals and new patients. Schedule a consultation today.

As surgeons, many of the techniques used every day were learned during training. But are they still the best option for patients?

Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt, and foreign materials, including microorganisms from wounds. CHG acts as a preservative to inhibit microbial growth in the bottled solution. 1. Data on file at Irrimax Corp., Lawrenceville, GA

This October for National Physical Therapy Month, we’re celebrating the incredible physical therapists who help our patients regain strength, improve mobility and work toward greater independence. Meet Wallace, one of the talented physical therapists on the Innovive Health team! Inspired by a passion for helping others, he found his calling in physical therapy after working as an EMT and wanting to play a bigger role in patients' recovery journeys. His favorite part of being a PT is getting to know each patient, finding practical solutions to everyday challenges, and helping them regain confidence and independence. Whether it's climbing stairs, walking safely at home, or returning to activities they love, seeing those victories is what makes the job so rewarding. Interested in making a difference as a PT? Join the Innovive Health team and help patients work towards greater independence, just like Wallace. Explore open opportunities and apply today via innovivehealth.com/careers. #InnoviveHealth #Hiring #PT #PhysicalTherapy #NationalPhysicalTherapyMonth

Finding evidence is only the beginning. Causaly helps R&D teams evaluate and apply trusted scientific evidence through standardized, repeatable workflows giving scientists the transparency they need to make confident, defensible decisions.

Scientific research shouldn't depend on manual reviews, fragmented processes, and disconnected evidence. Causaly helps research teams surface trusted evidence, standardize scientific workflows, and move from insight to execution faster.

Embrace® HES is giving IRs a new option for treating hypervascular tumors. But a new option alone doesn't drive adoption. Physician experience and patient outcomes do. That's why we're so excited to sponsor this BackTable Vascular and Interventional episode, where host Venkatesh Krishnasamy sits down with Resmi Charalel, MD MPH FSIR, and Milan Patel for a case-based discussion of their firsthand experience with Embrace HES. Thank you to Dr. Charalel, Dr. Patel, and Dr. Krishnasamy for sharing your experience with the IR community. Listen on BackTable: https://lnkd.in/guYMA3Uq This episode was produced by BackTable and sponsored by Instylla. Views expressed are those of the participating physicians. Please refer to the Embrace HES Instructions for Use (IFU) for complete information regarding indications, contraindications, warnings, precautions, and directions for use. #LiquidEmbolics #LiquidEmbolization #BackTable #InterventionalRadiology #Embolization #EmbraceHES

Winter (mapping season) is coming ❄️ Are your mapping plans in place? Seasonal mapping is often a requirement in GMP-, GDP, and other GxP-regulated industries. Join Jakob Konradsen, author of "Mastering Temperature Mapping", for a webinar about seasonal mapping: Is it necessary for your operations? What special risks should you consider? And what do guidelines from WHO, FDA, and other regulatory bodies say about the subject? Sign up now 👇 Pssst… even if you’re not planning mappings this winter, we promise that there will be loads of golden nuggets helping you up your general mapping and validation game.

Deze online nascholing richt zich op de herkenning, diagnostiek en behandeling van episodische migraine in de dagelijkse praktijk. Doelgroep: Huisartsen, apothekers, neurologen en neurologen in opleiding 📅 Donderdag 29 oktober 2026 | 19:00 - 21:00 uur Tijdens presentaties en multidisciplinaire discussies komen onder andere de volgende onderwerpen aan bod: • Herkenning en diagnostiek van episodische migraine • Onderscheid tussen episodische en chronische migraine en medicatieovergebruikshoofdpijn (MOH) • Behandeling in de eerste lijn en samenwerking tussen de eerste en tweede lijn • Leefstijlinterventies en niet-medicamenteuze behandelopties • Preventieve behandeling van migraine Deelnemers kunnen tijdens het webinar actief deelnemen aan discussies en vragen stellen via de chat. 📍 Accreditatie is aangevraagd bij ABC1 voor huisartsen (2 punten). Dit programma komt onafhankelijk tot stand en wordt financieel mogelijk gemaakt door AbbVie. --- AGPT-NL-00031-E (v1.0) | Oct 2026

Help People Find Hope and Healing. Build a Nursing Career with Purpose. At Keystone Treatment Center, nurses do more than provide care, they help people reclaim their lives. We're seeking compassionate Registered Nurses (Days & Nights) to support patients receiving treatment for substance use and co-occurring mental health conditions. ✨ $10,000 Sign-On Bonus for FT Night Shift 💵 $32 - $48/hr 🩺 Day & Night Shift Opportunities 📈 Career growth with a leading behavioral healthcare organization ❤️ Meaningful work that changes lives For over 50 years, Keystone Treatment Center has been a trusted leader in addiction and mental health treatment. If you're passionate about healing, recovery, and serving your community, we invite you to join our team. Apply today and discover a nursing career with purpose.

Ireland's Presidency of the Council of the European Union comes at an important moment for Europe's life sciences sector. With competitiveness, innovation and the Biotech Act high on the agenda, the next months offer a real opportunity to turn ambition into action. In my conversation with Euractiv, I discuss what this means in practice: building a European policy framework that encourages research and incentivizes investment in health innovation, and strengthening the conditions that allow therapeutic breakthrough to thrive across Member States. A predictable, innovation-friendly environment is essential for Europe’s leadership in life sciences and, above all, for patients and healthcare systems. I look forward to continuing the conversation over the coming months. #IrishPresidency #Competitiveness #BiotechAct #EUHealth

Your employees are your greatest asset. Their wellbeing is your greatest investment. When mental health struggles go untreated, organizations pay the price. EHN Canada provides evidence-based treatment that helps employees recover, thrive, and stay engaged at work. Connect with EHN Canada today.

This World Mental Health Day, we reflect on your stories and our own. They inspire us to move mental health forward. #WorldMentalHealthDay #PsychadelicResearch #PsychadelicScience #MentalHealth #Biotech #TeamCompass

Studiare come agiscono le formule Aboca e valutarne l’efficacia per la salute delle persone è uno degli obiettivi principali della nostra ricerca clinica. Ad oggi abbiamo realizzato 18 studi clinici, 41 studi di ricerca di base e preclinica, oltre a 40 studi nell’area medica e farmacovigilanza e 20 nell’area regolatoria. Molti di questi studi sono stati pubblicati su riviste scientifiche di settore, una conferma della solidità delle nostre ricerche. Su questi temi leggi l'intervista completa ad Andrea Cossu, Medical Director del dipartimento di Medical Affairs Aboca, all'interno della nostra Relazione di impatto: https://lnkd.in/ei3HtS5r

For those of us who have been in the biopharmaceutical industry for a long time, the experience of working on "me too" or "me better" drug discovery programs is commonplace, and the privilege of working on novel targets supported by powerful causal biology, such as osteoprotegrin, sclerostin and PCSK9, is quite quite rare. 38 targets now have more than 50 programs against each of them, while the number of novel targets advanced per year fell from roughly 100 in 2015 to about 30 in 2024. For 8 years insitro has been working to reverse this trend. Please read about our journey in the first of a multi-part series "Deep Phenotype: Scaled Biology, Deep Causality": https://lnkd.in/gRyMFA2y #AI #ML

Leveraging Platform Innovation to Tackle Tough Targets https://lnkd.in/eVU5xFCa Thursday, October 22nd, 2026 8 AM PT | 11 AM ET | 5 PM CET Drug discovery is increasingly focused on biological targets once considered undruggable. In this difficult-to-drug space, success depends on understanding how the target should be modulated, identifying molecules capable of delivering the desired mechanism, and rapidly establishing confidence in their activity. In this Flash Talk, Andrea Weston, Head of Discovery Biology and Pharmacology at Pfizer, will explore how the thoughtful integration of platform technologies can improve the probability of success against challenging targets. She will highlight how the right protein reagents and cellular models can be critical to successful lead identification, and how defining the desired mechanism of action before screening can better position programs for success. Andrea will also examine current hit-finding strategies and emerging approaches for elucidating small-molecule MoAs, sharing how these advances are collectively expanding the boundaries of druggability and creating new opportunities to discover transformative medicines. Register now to learn more about recent advances in platform technologies and their applications towards difficult-to-drug targets: https://lnkd.in/ejdut4Jg

In the latest issue of Cell, insitro founder and CEO Daphne Koller joins researchers from across the life sciences in sharing perspectives on how AI is transforming biomedical research — and what it will take to turn today's advances into deeper biological understanding. In her contribution, "Causal AI won't emerge on its own," Daphne argues that the challenge ahead is not scaling AI models, but generating the right data to teach them cause and effect in human biology. Gaining this insight depends on dual pillars of proof: naturally occurring randomized trials via genetic diversity within broad patient populations, alongside genome-scale perturbation experiments. Isolated, neither provides a complete picture. Combined, they empower our platform to bridge observation with biological cause, addressing the essential question in therapeutic development: what occurs when we intervene on this specific target? By producing this data at massive scale, insitro powers the Virtual Human™ – a genetically anchored AI engine that reveals how disease begins, progresses, and can be resolved; and our TherML™ platform, which designs medicines against the causal drivers it identifies. Every disease we interrogate makes the model smarter, compounding our lead as the corpus grows. "The goal was never a virtual cell. It is a causal model of a multi-scale human." 📖 Read the full essay in Cell: https://lnkd.in/gMetMntU 🔎 More from Daphne on causal AI in Deep Phenotype, insitro's official Substack publication: → “Drug Discovery Has No Magic Wands” - https://lnkd.in/dGK8DBeq → “Mapping Causal Human Biology” - https://lnkd.in/gkWwXQeW #AI #DrugDiscovery #CausalBiology

What is changing the way early phase oncology trials are delivered? From specialized Phase I oncology centres to site networks and closer site-CRO collaboration, new approaches are reshaping early phase trial delivery. Dr Shiraj Sen, Director of Clinical Research at NEXT Oncology, shares his perspectives on what sponsors should consider when planning and executing early phase oncology trials. Explore the full 3-part video series.